Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance. In this newly created role, Ms. Riethuisen will oversee corporate development, finance and strategic planning and serve as treasurer and company secretary.

“We are thrilled to welcome Véronique to Cedilla. She has an impressive track record shaping and building early and late-stage portfolios for leading biopharmaceutical companies,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Véronique’s substantial leadership experience, coupled with her background in corporate and business development, will be instrumental in growing Cedilla. We look forward to her contributions as we execute on our vision of leveraging our novel small molecule drug discovery approach to address the needs of patients with cancer and other diseases.”

“I am honored to join the Cedilla team. Cedilla has developed a novel approach to addressing undruggable targets for the treatment of cancers and diseases caused by protein dysregulation,” said Ms. Riethuisen. “I look forward to working together with my new colleagues to progress a growing portfolio of promising medicines for the benefit of patients.”

Ms. Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla. Most recently, Ms. Riethuisen served as Senior Vice President, Global Business Development and Strategic Alliance Management at Ipsen where she helped build Ipsen’s rare disease franchise by acquiring and licensing multiple innovative assets for the treatment of fibrodysplasia ossificans progressiva. She also negotiated Ipsen’s global agreement with Debiopharm for Decapeptyl®, an achievement recognized with the 2020 Award for “Long-Established Alliance” from the Association of Strategic Alliance Professionals. Prior to Ipsen, Ms. Riethuisen was Vice President, Head of Global Transactions at Takeda where she led a team that, in just one year, successfully landed over 20 deals transforming the company’s gastrointestinal and regenerative medicine portfolios. Earlier, Ms. Riethuisen held various business development, M&A and alliance management roles of increasing responsibility at Pfizer, Teva, Bristol Myers Squibb and Monsanto. Ms. Riethuisen currently serves as an Executive Coach for the MassNextGen program mentoring first-time female chief executive officers, and she teaches a Business Development Fundamentals course annually in conjunction with the BIO Annual Conference. Ms. Riethuisen holds a bachelor and master’s degree in Applied Economics from the University of Brussels (ULB), Belgium.

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Contacts

Investor Contact:
Hannah Deresiewicz

Stern Investor Relations, Inc.

hannah.deresiewicz@sternir.com
212-362-1200